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To study the role of smoking in renal damage, we measured
gender-specific effects, dose-response relationships, and
whether cessation reduced the risk of smoking on future
kidney failure. During a median follow-up of 10.3 years,
124 of 65,589 participants of the HUNT II study, a Norwegian
population, progressed to stage 5 chronic kidney disease.
Former- and current-smokers less than 70 years of age at
inclusion had significant multi-adjusted hazard ratios of 3.32
and 4.01 for kidney failure compared to those who never
smoked. In men, the risk increased with a significantly higher
trend for cumulative smoking (pack-years); however, the risk
significantly decreased with increased elapsed years since
smoking cessation. Although the prevalence of current
smoking did not differ between genders, females had
smoked less (10.2 compared to 15.8 pack-years) and the
number of kidney failure cases was lower in females than
in men (46 compared to 78). The effect of smoking on the
risk of kidney failure was similar (hazard ratios of 2.94 and
4.30 in current-smoking women and men, respectively),
but did not reach statistical significance in women.
Thus, in this large population-based sample, we found that
smoking is a significant risk factor for future kidney failure.
Smoking cessation decreased this risk, at least in men.
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The worldwide high prevalence of chronic kidney disease
(CKD) and the strong increase in the incidence of patients
reaching end-stage renal disease have urged nephrologists to
identify renal risk factors. In recent years it has become
apparent that cigarette smoking, besides its traditionally
accepted carcinogenic effects and its detrimental role as a
promoter of cardiovascular disease (CVD), is an important
independent renal risk factor. Despite a substantial number
of studies documenting a deleterious effect of smoking on
renal function (see Orth and Hallan1 for review), several
important aspects of smoking-induced renal damage remain
unclear. Although there are enough nonrenal reasons to not
smoke, establishing smoking as an independent risk factor for
kidney failure is important for improving focus and
motivation for smoking cessation among CKD patients and
to further increase awareness about this renal risk factor
among nephrologists.
First, it is controversial whether the renal effects of
smoking equally affect both genders. A large population-
based study from Australia including 11,247 randomly
selected subjects found lifetime smoking exposure to be
significantly associated with CKD stage 3 or higher in men,
but not in women.2 However, other studies have reported
similar effects of smoking on the risk of kidney failure in both
genders.3,4 Second, it is unclear whether the smoking-related
risk of kidney failure depends on the amount of cigarettes
smoked. Dose-response relationships have only been demon-
strated for surrogate end points like renal function decline
and urine albumin excretion rate.5,6 Third, it is unknown to
what extent smoking cessation reduces the risk of kidney
failure. Very few studies have investigated this topic, and data
are based on a limited number of patients with diabetes
mellitus, again using only surrogate markers of renal damage,
that is, no hard end points.7–9 Data from general population-
based subjects are not available at all.
Therefore, the aim of the present study was to investigate
how the above-mentioned aspects of smoking influence the
risk of kidney failure in a large population-based sample.
Smoking susceptibility could be different in men and women,
and it is also increasingly clear that the excess risk caused by
smoking may be apparently weakened in the elderly because
or ig ina l a r t i c l e http://www.kidney-international.org
& 2011 International Society of Nephrology
Received 17 September 2010; revised 29 March 2011; accepted 5 April
2011; published online 15 June 2011
Correspondence: Stein I. Hallan, Department of Medicine, Division of
Nephrology, St Olav University Hospital, N-7006 Trondheim, Norway.
E-mail: stein.hallan@ntnu.no
516 Kidney International (2011) 80, 516–523
of differential survivorship and competing risks in ever-
smokers, that is, a survival bias.10–12 This phenomenon
extends to several cardiovascular risk factors,13 and several
studies show that the genetic background plays an important
role for the susceptibility of individual subjects to smoking-
related damage.14,15 Thus, to avoid the presence of a survival
bias in elderly smokers, we separately investigated men and
women o70 years and X70 years of age at study start.
RESULTS
Among the 65,589 participants, 45.0% were never-smokers,
26.1% were former-smokers, 27.7% were current-smokers,
and information about the smoking status was missing in
1.2%. Baseline characteristics of these four groups are given
in Table 1. Mean (s.d.) length of smoking among current-
smokers was 25.6 (13.3) years, whereas mean time since
quitting smoking in former-smokers was 14.8 (11.3) years.
The smoking pattern was slightly different in women
compared with men: 20.3% vs 33.4% were former-smokers
and 27.4% vs 28.6% were current-smokers, respectively. The
number of cigarettes consumed per day by current-smokers
was 10.0 (4.8) in women vs 12.3 (6.3) in men. The cumulative
smoking dose among former-smokers was 7.4 (7.9) pack-
years in the female population vs 14.2 (13.7) pack-years
in the male population, and corresponding numbers
among current-smokers were 12.1 (8.8) and 17.3 (12.4),
respectively.
The cohort had a median observation time of 10.3 years
(range 0.1–11.3), and 124 patients (78 men and 46 women)
progressed to kidney failure (CKD stage 5): 58 started renal
replacement therapy (RRT) and in 66 others the cause of
death reported was CKD with an estimated glomerular
filtration rate (eGFR) of o15ml/min per 1.73m2 documen-
ted in their medical records. Table 2 shows the multiadjusted
risk of future kidney failure conferred by smoking using Cox
proportional hazard regression analysis. In subjects below age
70 at study start, former-smokers had a 3.3 times higher risk
(P¼ 0.02) and current-smokers had a 4.0 times higher risk
(P¼ 0.01) compared with never-smokers, respectively. In
subjects above age 70, the associations were attenuated and
neither former-smokers nor current-smokers had a signifi-
cantly increased risk of kidney failure. Independent of age,
the two major baseline predictors of future kidney failure
were albuminuria and eGFR, but gender and systolic
blood pressure were also significant, although less powerful
risk factors.
In subjects below age 70, the renal risk associated with
ever-smoking was 4.3 (P¼ 0.02) among men and 2.9
(P¼ 0.10) among women. In subjects X70 years old, there
was no significant association of kidney failure risk with
smoking, neither in men nor women. Table 3 also shows the
risk of kidney failure associated with former- and current-
smoking. Multiadjusted hazard ratios (HRs) are displayed for
a combined smoking–gender variable using never-smoking
men and women, respectively, as the reference category.
Figure 1 shows the distribution of subjects and kidney failure
cases in men and women by total smoking dose and time
since smoking cessation, respectively. In women, there were
very few subjects with a moderate to high smoking dose and
nearly no kidney failure cases. Likewise, there were less than
five kidney failure cases in each group of former-smoking
females. Therefore, further analyses of dose-response
relationships and the effect of smoking cessation were limited
to men.
Tables 4 and 5 illustrate the influence of smoking dose and
of smoking cessation on the risk of kidney failure in men
below age 70. Table 4 shows that total smoking dose had a
strong independent effect on the risk of kidney failure. The
risk increased nearly linearly with increasing number of pack-
years (P for trend o0.001). For example, a man who had
smoked 20 cigarettes (that is, one ‘pack’) for 15 years (that is,
15 pack-years) had a ninefold higher kidney failure risk
compared with never-smokers. Table 5 shows that time since
quitting was related to kidney failure risk. Former-smoking
males who had quitted many years ago had only a moderate
increased risk whereas those having quitted more recently
had a much higher kidney failure risk (P for trend¼ 0.005).
A total of 6% of current-smokers reported smoking cigars
or pipe, and their risk could be different from cigarette
smokers. We therefore performed a sensitivity analysis where
cigar and pipe smokers were excluded. All results remained
unchanged. For example, the adjusted HR associated with
former and current smoking in subjects below age 70 years
was 3.3 and 3.6 compared with 3.3 and 4.0 in the original
analyses. Furthermore, to reduce the effect of survival bias,
we performed a competing risk analysis using the ‘stcrreg’
procedure in STATA (Stata, College Station, TX), which is
able to handle multiple imputed data sets. However, neither
this analysis allowed us to use the total cohort in a common
analysis: when using the total material, no significant effect of
smoking was found, restricting to age o70 gave a significant
effect, that is, similar to our previous analyses.
DISCUSSION
Using this large population-based sample with a median
follow-up of 10.3 years and a hard clinical end point, we were
able to investigate the deleterious effect of smoking on renal
function in detail. In subjects below age 70, current-smokers
had a 4.0 times and former-smokers had a 3.3 times higher
risk of kidney failure when compared with never-smokers,
respectively. The risk seemed to be similar in men and
women and was independent of all known major renal risk
factors. A significant influence of the cumulative smoking
dose and the time since quitting was found in men. This
could not be documented in women because of the low
number of females with a high cumulative smoking dose and
the low number of kidney failure cases observed in this
subgroup.
Many studies have assessed the effect of smoking on renal
function, but study design and samples have varied
considerably.1 Significant associations have been found
between smoking and surrogate end points like kidney
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Table 1 | Baseline data by smoking category
Smoking categories
Variable (n)
Never
(n=29,515)
Former
(n=17,119)
Current
(n=18,168)
Unknown
(n=787)
Smoking
Length (years) NA 19.1 (13.5) 25.6 (13.3) NA
Time since quitting (years) NA 14.8 (11.3) NA NA
Pack-years NA 11.4 (12.8) 14.5 (11.1) NA
Cigarette smoker NA NA 94 NA
Age (years) 49.2 (18.8) 54.4 (15.7) 46.9 (14.6) 71.6 (18.9)
Male gender 40.4 59.2 45.8 37.9
High education 37.0 25.0 21.2 21.9
Physical inactivity 18.4 19.6 23.3 27.4
Diabetes mellitus 3.5 4.3 2.0 10.9
Cardiovascular disease 6.3 13.0 5.6 15.3
Treated hypertension 11.8 14.4 6.7 20.6
Systolic blood pressure 139.0 (22.6) 140.1 (21.7) 133.7 (19.7) 149.3 (26.1)
BMI (kg/m2) 26.5 (4.2) 27.0 (16.2) 25.6 (4.0) 27.0 (4.6)
Total cholesterol (mg/dl) 224 (50) 232 (46) 228 (46) 228 (54)
HDL cholesterol (mg/dl) 54 (15) 54 (15) 50 (15) 46 (15)
ACR (mg/g) 22.6 (85.6) 34.2 (118.4) 31.7 (105.1) 33 (66.6)
eGFR (ml/min per 1.73m2) 97.9 (20.5) 93.8 (18.7) 102.5 (16.8) 78.2 (23.3)
Abbreviations: ACR, urine albumin-to-creatinine ratio; BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL cholesterol, high-density lipoprotein cholesterol;
NA, not applicable.
Categorical data are presented as percent, and continuous data are presented as mean (s.d.).
Table 2 |Multiadjusted risk for future kidney failure according to age at study start
Age o70 years Age X70 years
HR 95% CI P-value HR 95% CI P-value
Smoking
Never-smoker 1.00 1.00
Former-smoker 3.32 1.23–8.85 0.02 0.84 0.47–1.50 0.56
Current-smoker 4.01 1.43–11.25 0.008 1.09 0.51–2.33 0.82
Age (per 10 years) 0.64 0.46–0.88 0.006 1.21 0.82–1.89 0.41
Female gender 0.65 0.32–1.34 0.25 0.28 0.15–0.50 o0.001
High education 2.35 1.03–5.31 0.04 1.02 0.39–2.64 0.97
Physical inactivity 2.44 1.11–5.37 0.03 1.65 0.92–2.97 0.09
Diabetes mellitus 2.55 1.00–6.48 0.05 1.25 0.62–2.51 0.54
Prevalent CVD 0.26 0.09–0.78 0.02 0.88 0.53–1.44 0.61
Antihypertensive medication 1.19 0.55–2.58 0.65 0.92 0.56–1.52 0.75
Systolic blood pressure (per 10mmHg) 1.27 1.11–1.46 0.001 1.10 1.01–1.20 0.04
Waist circumference (per 10 cm) 1.16 0.98–1.55 0.30 0.96 0.76–1.22 0.75
Total/HDL cholesterol 1.09 0.94–1.28 0.26 1.15 1.02–1.28 0.02
eGFR (per 10ml/min per 1.73m2) 0.33 0.28–0.39 o0.001 0.45 0.40–0.52 o0.001
ACR (per 88mg/g) 1.20 1.11–1.30 o0.001 1.17 1.11–1.23 o0.001
Abbreviations: ACR, urine albumin-to-creatinine ratio; CI, confidence interval; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high density
lipoprotein; HR, hazard ratio.
HRs were adjusted for all the variables displayed in the table.
Table 3 |Multiadjusted risk for kidney failure in men and women below age 70
Never-smoking men as reference category Never-smoking women as reference category
Men Women Women Men
Never-smoker 1.00 0.87 (0.20–3.70) 1.00 1.13 (0.27–4.90)
P=0.9 P=0.9
Former-smoker 3.74 (1.05–13.20) 2.77 (0.65–11.95) 3.19 (0.76–13.52) 4.30 (1.31–14.05)
P=0.04 P=0.2 0.10 0.02
Current-smoker 5.75 (1.46–22.61) 2.40 (0.52–11.15) 2.77 (0.64–11.93) 6.62 (1.73–25.36)
P=0.01 P=0.3 P=0.2 P=0.01
The association of kidney failure with smoking in men and women was calculated using a six-category combined smoking–gender variable. To show the association in men,
we used never-smoking men as the reference category (i.e., the interesting results showing the effects of smoking in men are in the gray-shaded column to the left). A similar
analysis was done with never-smoking women as the reference category (i.e., the two columns to the right). Data are given as hazard ratio (95% confidence interval) and all
Cox analyses are adjusted for age, education, physical activity, diabetes mellitus, prevalent cardiovascular disease, antihypertensive medication, systolic blood pressure, lipids,
waist circumference, estimated glomerular filtration rate, and albumin–creatinine ratio.
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function and albuminuria in cross-sectional, population-
based studies.2,6,16,17 Although low eGFR and increased
albuminuria are very strong risk factors for progression to
kidney failure, cross-sectional studies are hampered by
substantial limitations. In contrast, prospective population-
based studies allow to draw much more significant conclu-
sions, and in studies with this latter design smoking has been
associated with significant changes in kidney function.4,5
However, only few studies have previously reported on the
effect of smoking using hard clinical end points (see Orth
and Hallan1 for review), and smoking-related kidney failure
was often not the primary focus of these studies. As one of
the most relevant studies, Haroun et al.3 followed 23,534 US
subjects for 20 years and found that current smoking was
associated with the HR of 2.6 for future RRT or having
kidney disease listed on the death certificate compared with
former- and never-smokers. Of note, this analysis could only
be adjusted for age, gender, blood pressure, and diabetes
status, as there was no information on baseline serum
creatinine, lipids, urinary albumin, and other relevant renal
risk factors. Bash et al.18 followed 15,324 participants of the
Atherosclerosis Risk in Communities study for 16 years and
found an adjusted HR for serious kidney-related events
(transplantation, acute or chronic dialysis, or death) of 1.6 in
former-smokers and 1.9 in current-smokers, respectively. On
the contrary, Hsu et al.19 followed 177,570 subjects of the
Kaiser Permanente cohort in California for 25 years and did
not find that smoking was a significant risk factor for end-
stage renal disease after adjusting for other relevant renal risk
factors. The reason for this difference is unclear, but
substantial changes in lifestyle risk factors could have taken
place during the long observation period of the latter cohort,
and no correction for time-related changes in risk exposure
was done. Current smoking was reduced from 38% at study
baseline to 13% according to a survey of Californian adults in
2000,20 that is, the end of the observation period of the study
by Hsu et al.19 In summary, there is substantial evidence that
smoking leads to an increased risk of serious kidney damage
leading to kidney failure in the end. Our current study
strongly supports this general finding, but several important
aspects need further consideration and have been addressed
in the present study.
Gender-specific kidney effects of smoking have been
suggested in several studies, with men being more susceptible
than women.2,21,22 In the cross-sectional Aus-Diab study an
association between smoking and eGFR o60ml/min per
1.73m2 was found in men only,2 and women had no
increased risk of proteinuria in a Japanese cohort.22 This is
contrasting sharply with the fact that for major health
outcomes like cancer and CVD, studies have repeatedly found
women to be more susceptible to smoking than men.23,24
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Figure 1 |Distribution of study participants and outcomes.
Panel a displays data by total (cumulative) smoking dose. Panel b
displays data by time since smoking cessation.
Table 4 | Influence of total smoking dose on the risk of kidney failure in men below age 70 years
Unadjusted Adjusted for age, eGFR, and ACR Multiadjusted
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Never-smokers 1.00 1.00 1.00
1–9 pack-years 1.18 0.22–6.29 0.8 4.10 0.62–26.6 0.1 4.21 0.50–35.16 0.18
10–19 pack-years 3.35 0.90–12.5 0.07 6.62 1.38–31.5 0.02 8.84 1.58–49.89 0.01
20–39 pack-years 5.93 1.73–20.1 0.004 11.1 2.50–49.9 0.002 13.5 2.20–81.5 0.005
X40 pack-years 17.6 4.43–70.1 o0.001 14.0 2.75–70.8 0.001 37.7 4.17–336 0.001
Test for trend o0.001 o0.001 o0.001
Abbreviations: ACR, urine albumin-to-creatinine ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio.
Data are HRs, 95% CIs, and P-values from Cox proportional hazard regression analyses. The multiadjusted analysis was adjusted for age, education, physical activity, diabetes
mellitus, prevalent cardiovascular disease, antihypertensive medication, systolic blood pressure, lipids, waist circumference, and kidney status (eGFR and ACR).
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However, other studies have demonstrated that smoking
increases the risk of low eGFR in both men and women in
population-based case–control and cross-sectional stu-
dies,17,25 and even more importantly, equal risk of serious
CKD was found in a longitudinal study.3 Our study
seems to confirm the detrimental effect of smoking in both
men and women, even after adjusting for current kidney
function and other important renal risk factors. Although we
included 35,000 women with equal current-smoking
prevalence as in men, total smoking dose was lower and
progression to kidney failure occurred in very few females.
The relative risk in ever-smoking women was very similar to
the male results, but it did not reach full statistical
significance (P¼ 0.10).
A dose-response relationship is usually considered as
evidence supporting causality. For smoking and kidney
damage such evidence has not been documented in a
satisfactory way so far. A significant association has been
found between the number of cigarettes and surrogate end
points like low eGFR and albuminuria in cross-sectional and
case–control studies from the general population.2,5,25,26
Stengel et al.27 followed 9082 NHANES (National Health
and Nutrition Examination Survey) II participants for 13.2
years in one of the very few population-based cohort studies
available investigating this topic. The adjusted risk of RRT or
CKD death was 1.4 (95% confidence interval 0.7–2.7) times
increased in the group smoking 1–20 cigarettes per day, and
the risk was 2.3 (1.2–4.3) for those smoking 420 cigarettes
per day. This could indicate a threshold effect, but the results
could be biased as the rather imprecise ‘CKD as a
contributing cause of death’ was the most frequent study
outcome and baseline serum creatinine was missing in 31%
of study participants. We found that in men there was a clear
trend of increasing risk for RRT or CKD death with a
documented eGFR o15ml/min per 1.73m2 with increasing
number of ‘pack-years’ with no apparent threshold. Thus, the
current scarce evidence for a dose-response relationship of
smoking and kidney failure is substantially strengthened by
the data that we obtained analyzing the HUNT II study
population, at least as far as men are concerned.
An investigation about the role of age in the context of
smoking-associated renal risk has not been done so far, but
studies including only elderly people have found that
smoking is an important risk factor even in this subgroup.
Baggio et al.28 studied 2981 elderly subjects from Italy and
found that smoking420 cigarettes per day was a very strong
risk factor for a pathological loss of kidney function. Other
studies have found similar results.5,29 In contrast, we did not
find an increased risk of kidney failure in elderly smoking
participants in the HUNT II study. A hypothesis that
smoking is not harmful in elderly is biologically not very
plausible, and hence study-related explanations for our
findings should rather be sought. A ‘smoker’s paradox’, that
is, improved outcomes in the smoking group, has been
reported in heart failure,30 and a smoking-related survival
bias has been shown to be of statistical relevance in both
cohort and case–control studies.31 Other examples on ‘reverse
epidemiology’ have been documented for well-established
risk factors like blood pressure, cholesterol, and body mass
index in patients with chronic obstructive pulmonary disease,
rheumatoid arthritis, end-stage renal disease, and the
elderly.32 Survival bias, which is a form of selection bias that
might heavily influence the epidemiologic associations in
subgroups of cardiovascular survivors, is probably one of the
major mechanisms leading to these inverse associations.
Those who manage to survive long enough to reach kidney
failure despite smoking may have other protective factors that
otherwise negate the adverse effects of smoking. As no
modern competing risk analysis was able to handle the
survival bias effect of age in our cohort, we separately
analyzed subjects o70 and X70 years of age, being aware
that this is not a perfect solution of this problem.
Our study has some limitations that must be discussed.
The validity of our smoking-related variables has not been
tested in the HUNT II study specifically. Smoking under-
reporting and change in smoking habits as well as other risk
factors during the observation period can lead to misclassi-
fication and contribute to an attenuation of our results,
whereas residual confounding can always lead to erroneous
associations in cohort studies. However, the well-known
associations between various smoking variables and cardio-
vascular mortality in both men and women have been found
in previous HUNT publications, which strengthen the
validity of our kidney failure results.33,34 Other studies have
Table 5 | Influence of time since smoking cessation on the risk of kidney failure in men below age 70 years
Unadjusted Adjusted for age, eGFR, and ACR Multiadjusted
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
1–4 years 3.45 0.64–18.7 0.2 10.5 1.32–82.3 0.03 21.5 2.04–225 0.01
5–9 years 4.90 0.90–26.8 0.07 19.9 2.48–154 0.005 40.4 3.71–441 0.002
10–19 years 3.78 0.85–16.9 0.08 9.49 1.43–62.8 0.02 7.10 0.59–85.6 0.12
X20 years 8.16 2.34–27.9 0.001 8.84 1.70–45.6 0.009 10.5 1.45–75.9 0.02
Never-smokers 1.00 1.00 1.00
Test for trend 0.06 0.01 0.006
Abbreviations: ACR, urine albumin-to-creatinine ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio.
Data are HRs, 95% CIs, and P-values from Cox proportional hazard regression analyses. The multiadjusted analysis was adjusted for age, education, physical activity, diabetes
mellitus, prevalent cardiovascular disease, antihypertensive medication, systolic blood pressure, lipids, waist circumference, and kidney status (eGFR and ACR).
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found that misclassification of smoking status is low (10%)
in both general populations and more ‘vulnerable’ groups
like pregnant women and patients with acute coronary
syndromes.35–37 Furthermore, we were not able to adjust for
the use of therapeutic drugs, which also may have changed
during follow-up. Although HUNT II is a large study, kidney
failure is a rare outcome that could lead to analytical
problems. For example, high education turned out to be a
borderline significant risk factor in Table 2. This is probably
just a kind of coincidence, dependent on the many
other variables in the model, as the crude education
effect (as well as after adjusting for age, sex, smoking, eGFR,
and urine albumin-to-creatinine ratio) was close to HR 1 and
not significant. The generalizability of our results to other
ethnic groups and countries can also be debated, as strikingly
different consequences of smoking have been reported
depending on the populations investigated.38
However, our study also has several strengths. We included
a large number of participants from a prospective cohort
study with a very high participation rate, which substantially
reduces the risk of selection and information bias. Informa-
tion on many potential confounders was available and could
be adjusted for, and missing data were handled by multiple
imputations to avoid loss of power and biased estimates. The
major focus of our analysis was on smoking-related kidney
failure, and dose-response relationship and the effect of
quitting smoking could be tested. We used a hard clinical end
point also including kidney failure patients not treated with
dialysis, which is a large and important group and an
increasingly discussed treatment option.39,40
The clinical implications of ours as well as previous results
are obvious, although randomized controlled trials with hard
clinical end points like kidney failure risk after quitting
smoking are not available (it might even be unethical to carry
out such studies nowadays). All CKD patients should now be
very strongly encouraged to quit smoking. This has probably
not been highlighted sufficiently in clinical practice even if
clearly stated in the 2002 KDOQI (Kidney Disease Outcomes
Quality Initiative) guidelines. At that time, the deteriorating
effect of smoking on kidney function was not very well
documented. A further rational is the very high risk of
cardiovascular death among CKD patients.34,41 For CKD
stage 1–3 patients, serious cardiovascular events are much
more probable than progression to kidney failure.42 Smoking
has been documented to be a significant cardiovascular risk
factor even in CKD stage 5 patients.43
Regarding smoking and kidney pathophysiology, direct
vascular effects are probably a major mechanism. Smoking is
particularly associated with atherosclerosis in the aorta and
lower extremity arteries,44,45 and increased stiffness of central
vessels causes increased energy transmission to low-resistance
arterioles in the kidneys, which is a key factor in the
pathogenesis of glomerular and tubular damage.46 This could
potentiate the effect of media calcification caused by
disturbances in vitamin D and calcium–phosphate metabo-
lism.47 More direct mechanisms of smoking-induced kidney
damage are also possible; for example, it has been suggested,
based on experimental studies, that nicotine could promote
mesangial cell proliferation and spur on critical molecules
that are involved in the extracellular matrix production.48,49
In summary, associations between smoking and CKD have
been found in various studies with more or less optimal
design. The current study investigated the deleterious effect
of smoking on renal function in detail using a large
population-based sample with long follow-up, adjusting for
all relevant confounders, and using a hard clinical end point.
We found that the risk of kidney failure was three to four
times higher in smokers. Furthermore, a significant influence
of the cumulative smoking dose and a decreasing risk after
smoking cessation was documented. Thus, all CKD patients
should now be very strongly encouraged to quit smoking,
and if necessary given psychological and/or pharmacological
support to achieve this very important goal. In this context,
our finding of a progressive decrease in renal risk with
increasing time since smoking cessation is very encouraging.
Efforts to investigate smoking cessation strategies for the
specific group of CKD patients are warranted.
MATERIALS AND METHODS
The HUNT II study is a Norwegian large-scale general health survey.
From 1995 to 1997, all individuals residing in Nord-Trøndelag
county (97% Caucasians) agedX20 years were invited. Participants
answered a comprehensive questionnaire, underwent clinical
examination, and donated a blood sample. A more detailed
description of the objectives, methods, and participation in the
HUNT II study has been given elsewhere.50 The participants gave
informed consent, including linkage to central national registries.
The current study was approved by the Regional Committee for
Medical Research Ethics, the Norwegian Data Inspectorate and the
Ministry of Health.
Of 92,939 subjects invited, 65,604 responded, representing 70.6%
of the entire adult population. All participants reported on current
and former health, illness in the family, education, and risk factors
such as physical inactivity. Smoking was assessed by a set of
questions: (1) Have you ever smoked? (2) Do you currently smoke
cigarettes/cigars/pipes? (3) When did you start smoking? (4) When
did you stop smoking? (5) How many cigarettes did/do you usually
smoke per day? Three consecutive standardized blood pressure
measurements were recorded in the sitting position (Dinamap
845XT; Criticon, Tampa, FL). Subjects were classified according
to diabetes mellitus (self-report or non-fasting blood glucose
X11.2mmol/l), treated hypertension (self-report of high blood
pressure needing drug treatment), high education (412 years at
school), physical inactivity (o60min of light exercise and no hard
exercise per week), and prevalent CVD (self-reported angina
pectoris, myocardial infarction, or stroke).
Blood was obtained from all participants, immediately centri-
fuged and refrigerated, and analyzed within 2 days using a Hitachi
911 autoanalyzer (Hitachi, Mito, Japan). The original Jaffe´-based
creatinine values were recalibrated, providing isotope dilution mass
spectrometry traceable values. GFR was estimated with the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation,
which has a minimal negative bias even at near-normal GFR levels.51
Subjects with an eGFR o15ml/min per 1.73m2 (n¼ 15) were
excluded, and subjects with eGFR values X160ml/min per 1.73m2,
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which is unlikely to be physiological, were given a value of 160ml/
min per 1.73m2 (n¼ 541).
By design, subjects with treated hypertension, diabetes mellitus,
and a random 5% sample of nondiabetic nonhypertensive subjects
were asked to deliver spot urine samples on three consecutive
mornings. In all, 85.3% returned all requested urine samples. The
nonresponders were not statistically different from those delivering
all urine samples regarding important variables like age, gender,
CVD, weight, blood pressure, lipids, and serum creatinine. Albumin
concentration in the urine was measured within 5 days using an
immunoturbidimetric method (Dako A/S, Glostrup, Denmark).
The study outcome was future kidney failure (CKD stage 5),
defined as starting RRT or decrease of eGFR to o15ml/min per
1.73m2 (ref. 52). The national identification number given to all live
births enabled record linkage to the Norwegian Renal Registry and
the Cause of Death Registry in all participants. We used CKD death,
defined as ICD-10 (International Statistical Classification of Diseases
and Related Health Problems 10th Revision) diagnosis N00–N19
excluding N17, to find subjects with kidney failure not starting RRT.
Two experienced nephrologists manually searched hospital and
general practice records to ensure that all cases had a documented
CKD diagnosis before death and a documented eGFR o15ml/min
per 1.73m2 or other indications for chronic dialysis.
Statistical analyses were performed using Stata 10.0. We decided
beforehand to do separate analyses for subjectso70 andX70 years
of age at study start because of possible survival bias. Multivariable
analyses were performed using Cox regression adjusted for potential
confounders available: age, gender, diabetes mellitus, hypertension,
physical activity, prevalent CVD, total/high-density lipoprotein
cholesterol, waist circumference, urine albumin-to-creatinine ratio,
and eGFR. To study the effect of smoking in men and women, we
analyzed the interaction between smoking and gender using a new
composite six-category variable (three categories of smoking and
two categories of gender).53 Gender-specific analyses were also
performed.
In general, there were o5% missing data for most variables,
including smoking. However, a complete case Cox survival analysis
would include only 85% of all subjects and 60% of all cases
experiencing future kidney failure. Furthermore, repeated measure-
ments of urine albumin-to-creatinine ratio were, by study design,
available only in a subgroup.54 Multiple imputation is now
considered the standard method for optimal use of available
data,55–58 whereas complete case analysis would yield too imprecise
as well as biased results. The multiple imputation technique
estimates the mean and uncertainty of the missing data in individual
subjects using all information from the actually observed data. The
assumptions for the method of ‘missing at random’ were met. Using
the Stata command ‘ice’ we created 20 complete data sets to achieve
maximum accuracy.59,60 Subsequently, the Stata command ‘micom-
bine’ was used to combine these data sets for subsequent use
together with standard statistical methods.
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